Wells Fargo Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

Benzinga Newsdesk www.benzinga.com Neutral 56.4%

Neg 0% Neu 56.4% Pos 0%

Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.